NCT05861128CompletedPhase 3
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
An Open-Label, Multicenter, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 207 (actual)
- First submitted
- 6 May 2023
- Start date
- 10 Nov 2023
- Primary completion date
- 4 Mar 2026
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Diseases
- Ankylosing spondylitis
- NCT number
- NCT05861128
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 207
- From 10 Nov 2023 to the primary completion date, 4 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- There were any grade ≥3 adverse events within 4 weeks prior to enrollment and no return to grade 1 or normal.
- Within 4 weeks prior to enrollment, participants had the following infectious diseases: tuberculosis infection requiring treatment; HIV-positive, syphilis, HBV infection, HCV infection.
Other
- The investigators considered participants unsuitable for this study.
Who the study is looking for
- The investigators concluded that the participants continued to benefit from treatment with Jaktinib.
- The participants have been fully informed and voluntarily signed informed consent.
- The participants completed the ZGJAK029 study for 16 weeks of treatment and visitation and had good compliance.
- The interval between the participants' first dose and the last dose of ZGJAK029 ≤ 4 weeks.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| RenJi Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.